+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Relation between plasma concentrations and cardiovascular effects of oral oxprenolol in man



Relation between plasma concentrations and cardiovascular effects of oral oxprenolol in man



European Journal of Clinical Pharmacology 8(1): 3-9



Oxprenolol, 40, 80 and 160 mg, was administered orally to seven healthy volunteers. Over the following eight hours repeated measurements were made of the plasma concentrations and effects on heart rate, myocardial contractility (PEPc) and systolic and diastolic blood pressure in recumbency, in the upright position and during physical effort at a work load of 120 watts on a bicycle ergometer. The maximum plasma levels and the area beneath the plasma concentration curves increased roughly in proportion to the dosage increment. No evidence of first-pass inactivation in the liver was found. The half-life of the drug in plasma was approximately 80 minutes, irrespective of the dose administered. Oxprenolol slowed heart rate, prolonged PEPc and lowered systolic blood pressure, by comparison with values recorded after a placebo. The effects were generally least marked in the recumbent position and most marked during effort, when a clear-cut dose-response relation was found. The pharmacodynamic effects of oxprenolol were compared with its concentration in plasma. Marked beta-receptor blockade still persisted eight hours after dosing, although at this time, after doses of 40 and 80 mg, the drug could not be detected in plasma.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 041217852

Download citation: RISBibTeXText

PMID: 786674

DOI: 10.1007/bf00616408


Related references

Reproducibility of oxprenolol plasma concentrations in young female volunteers following oral administration of an oxprenolol Oros dosage form. British Journal of Clinical Pharmacology 19 Suppl 2: 185s-190s, 1985

Influence of food intake on plasma oxprenolol concentrations following oral administration of conventional and Oros preparations. British Journal of Clinical Pharmacology 19 Suppl 2: 191s-195s, 1985

Effects of inflammatory disease on plasma oxprenolol concentrations. British Medical Journal 2(6188): 465-468, 1979

A comparison of slow release with conventional oxprenolol: plasma concentrations and clinical effects. British Journal of Clinical Pharmacology 3(3): 439-443, 1976

Hemodynamic effects and variations in plasma renin activity after single oral administration of oxprenolol. Cardiology 59(1): 41-48, 1974

Amiodarone and N-desethylamiodarone concentrations in plasma, red blood cells, and myocardium after a single oral dose: relation to hemodynamic effects in surgical patients. American Heart Journal 111(2): 280-285, 1986

Pre-dosing plasma concentrations and beta-adrenoceptor blocking effects during repeated once daily dosing with 160 mg sustained-release propranolol (Inderal LA) and 16/260 oxprenolol Oros to healthy volunteers. British Journal of Clinical Pharmacology 19 Suppl 2: 197s-201s, 1985

Pre dosing plasma concentrations and beta adrenoceptor blocking effects during repeated once daily dosing with 160 milligram sustained release propranolol inderal la and 16 260 oxprenolol oros to healthy volunteers. British Journal of Clinical Pharmacology 19(SUPPL 2): 197S-202S, 1985

Simultaneous determination of oxprenolol and 2H6-labelled oxprenolol in human plasma by gas chromatography/mass spectrometry. Biomedical Mass Spectrometry 12(6): 269-273, 1985

Oxprenolol placental transfer, plasma concentrations in newborns and passage into breast milk. British Journal of Clinical Pharmacology 18(3): 453-456, 1984

Plasma thrombomodulin concentrations in relation to cardiovascular risk factors in a population sample. Blood Coagulation and Fibrinolysis 4(3): 455-458, 1993

Comparison of the activity and plasma levels of oxprenolol slow release oxprenolol long acting propranolol and sotalol. European Journal of Clinical Pharmacology 17(6): 419-424, 1980

Rock climbing: observations on heart rate and plasma catecholamine concentrations and the influence of oxprenolol. British Journal of Sports Medicine 12(3): 125-128, 1978

Relation between unbound plasma concentrations and toxicity in a prolonged oral etoposide schedule. European Journal of Clinical Pharmacology 54(9-10): 677-683, 1998

Plasma concentrations of hormones affecting cardiovascular function in relation to mortality in severe congestive heart failure. Circulation 78(4 PART 2): II575, 1988